Key points are not available for this paper at this time.
The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.
Tewari et al. (Tue,) studied this question.